Dr. Sara Tolaney reviews practice-changing data from ESMO 2025 in early-stage HER2-positive breast cancer, highlighting major shifts in clinical practice with findings from DESTINY-Breast11 in the neoadjuvant setting and DESTINY-Breast05 in the post-neoadjuvant setting.
